SELB SELECTA BIOSCIENCES

Selecta Biosciences to Participate in Upcoming Investor Conferences

Selecta Biosciences to Participate in Upcoming Investor Conferences

WATERTOWN, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic therapies for autoimmune diseases, enhance gene therapies and mitigate unwanted immune responses to biologics, today announced that Company’s Management will participate in upcoming investor conferences in September.

Details on the conferences can be found below.

Cantor Fitzgerald’s Cell and Genetic Medicines Conference

Format: Panel presentation and one-on-one investor meetings, attending in-person

Panel Title: Ring Ring: Is That Large-Cap Pharma Calling? Importance of Established Partnerships in Place

Date: Thursday, September 15, 2022

Time: 8:00 a.m. ET

Location: New York, NY

To schedule a meeting with the Company, please contact your Cantor Fitzgerald representative.

Jefferies Cell and Genetic Medicine Summit

Format: Fireside chat and one-on-one investor meetings, attending in-person

Date: Friday, September 30, 2022

Time: 2:30 p.m. ET

Location: New York, NY

To schedule a meeting with the Company, please contact your Jefferies representative. The webcast of the fireside chat will be accessible in the section of the company’s website at .

About Selecta Biosciences, Inc.

Selecta Biosciences Inc. (NASDAQ: SELB) is a clinical stage biotechnology company leveraging its ImmTOR® platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. With a proven ability to induce tolerance to highly immunogenic proteins, ImmTOR has the potential to amplify the efficacy of biologic therapies, including redosing of life-saving gene therapies, as well as restore the body’s natural self-tolerance in autoimmune diseases. Selecta has several proprietary and partnered programs in its pipeline focused on enzyme therapies, gene therapies, and autoimmune diseases. Selecta Biosciences is headquartered in the Greater Boston area. For more information, please visit .

For Investors:

Bruce Mackle

LifeSci Advisors, LLC



For Media: 

Brittany Leigh, Ph.D.

LifeSci Communications, LLC



  



EN
12/09/2022

Underlying

SELBSELECTA BIOSCIENCES

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SELECTA BIOSCIENCES

 PRESS RELEASE
Free
SELB SELECTA BIOSCIE...

Cartesian Therapeutics Reports Second Quarter 2025 Financial Results a...

Cartesian Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update Initiated Phase 3 AURORA trial of Descartes-08 in myasthenia gravis Preliminary data from Phase 2 trial of Descartes-08 in systemic lupus erythematosus expected in 2H25 Initiation of Phase 2 pediatric basket trial of Descartes-08 in select autoimmune indications expected in 2H25 Approximately $162.1 million cash, cash equivalents and restricted cash as of June 30, 2025, expected to support planned operations into mid-2027, including completion of ongoing Phase 3 AURORA trial FREDERICK, Md....

August 7, 2025 1 EN
 PRESS RELEASE
Free
SELB SELECTA BIOSCIE...

Cartesian Therapeutics Announces New Employment Inducement Grants

Cartesian Therapeutics Announces New Employment Inducement Grants FREDERICK, Md., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to two new employees. On August 4, 2025, the Company issued to these employees options to purchase an aggregate of 5,750 shares of the Company’s common stock with an exercise price of $12.48, the closing trading price of the Company’s common stock on the Nasdaq Global Market on t...

August 5, 2025 1 EN
 PRESS RELEASE
Free
SELB SELECTA BIOSCIE...

Cartesian Therapeutics Announces New Employment Inducement Grants

Cartesian Therapeutics Announces New Employment Inducement Grants FREDERICK, Md., June 03, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to three new employees. On June 2, 2025, the Company issued to these employees options to purchase an aggregate of 26,350 shares of the Company’s common stock with an exercise price of $9.98, the closing trading price of the Company’s common stock on the Nasdaq Global Market on t...

June 3, 2025 1 EN
 PRESS RELEASE
Free
SELB SELECTA BIOSCIE...

Cartesian Therapeutics Announces First Participant Enrolled in the Pha...

Cartesian Therapeutics Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia Gravis FREDERICK, Md., May 30, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (“Cartesian” or the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that the first participant has been enrolled in its Phase 3 AURORA trial of Descartes-08 in patients with myasthenia gravis (MG). Descartes-08, Cartesian’s lead cell therapy candidate, is an autologous engineered chimeric anti...

May 30, 2025 1 EN
 PRESS RELEASE
Free
SELB SELECTA BIOSCIE...

Cartesian Therapeutics to Participate in the H.C. Wainwright 3rd Annua...

Cartesian Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ FREDERICK, Md., May 13, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that its management expects to participate in a fireside chat at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ on Tuesday, May 20, 2025, at 9:00 a.m. ET. A live webcast of the presentation and fireside chat is expected to be accessible in th...

May 13, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch